18F-AV-1451 [(F-18)T807] is in Phase 2 development as a diagnostic PET tracer for in vivo imaging of tau aggregate pathology in patients with AD and related neurodegenerative diseases characterized by the presence of tau pathology (Figure 1). Here, MAPT is linked to neurodegenerative disease.